MedTrace Logo

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

NCT07543250 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-21

No results posted yet for this study

Summary

A Multicenter, Observational Study on the Real-World Effectiveness and Safety of inavolisib Combined with Endocrine Therapy With or Without a CDK4/6 Inhibitor in Patients with HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.

Conditions

Interventions

DRUG

Inavolisib in Combination With ET

Inavolisib in Combination With ET

DRUG

Inavolisib in Combination With ET+CDK4/6i

Inavolisib in Combination With ET+CDK4/6i

Sponsors & Collaborators

  • xuliang

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-16
Primary Completion
2026-12-31
Completion
2027-07-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07543250 on ClinicalTrials.gov